Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) saw a downside of -1.29% to close Monday at $13.77 after subtracting -$0.18 on the day. The 5-day average trading volume is 1,719,000 shares of the company’s common stock. It has gained $14.21 in the past week. An average of 1,951,905 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,733,698.
IRWD’s 1-month performance is 12.87% or $1.57 on its low of $11.85 reached on 09/14/21. The company’s shares have touched a 52-week low of $8.78 and high of $14.27, with the stock’s rally to the 52-week high happening on 08/12/21. YTD, IRWD has achieved 20.90% or $2.38. However, the current price is down -3.50%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Aug 16, 57 days have gone by since the last insider trading activity for Ironwood Pharmaceuticals Inc. (IRWD). Silver Ronald (Principal Accounting Officer) most recently sold 567 shares at $13.48 per share on Aug 16. This transaction cost the insider $7,643. SVP, Chief Operating Officer, Rickard Jason, sold 680 shares at a price of $13.48 on Aug 16. Then, on Jun 14, Director Currie Mark G sold 23,571 shares at a price of $11.59 per share. This transaction amounted to $273,188.
The company’s PE ratio for the last five years has touched a high of 107.77 and a low of 3.820. IRWD stock has a beta of 1.31. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.42 while the price-to-book (PB) in the most recent quarter is 4.36.
As well, the company’s long term debt to equity for the quarter ending June 29 was 0.64, while the total debt to equity was 0.86. In terms of profitability, the gross margin trailing 12 months is 99.80%. The trailing 12-month EBITDA margin is 41.56% while for the period ending June 29; Ironwood Pharmaceuticals Inc.’s operating margin was 50.20%. The firm’s gross profit as reported stood at $386.39 million against revenue of $389.52 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 14.03% to $104.03 million, while revenue of $88.85 million was 14.59% off the previous quarter. Analysts expected IRWD to announce $0.23 per share in earnings in its latest quarter, but it posted $0.34, representing a 47.80% surprise. EBITDA for the quarter stood at more than $65.49 million. IRWD stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 495.46 million, with total debt at $464.56 million. Shareholders hold equity totaling $162.9 million
Let’s look briefly at Ironwood Pharmaceuticals Inc. (IRWD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 65.20% to suggest the stock is trending Neutral, with historical volatility in this time period at 25.69%.
The stock’s 5-day moving average is $13.70, reflecting a +4.64% or $0.61 change from its current price. IRWD is currently trading +12.87% above its 20-day SMA, +13.99% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +3.77% and +16.60% respectively.
Stochastic %K and %D was 82.93% and 86.47% and the average true range (ATR) pointed at 0.42. The RSI (14) points at 62.43%, while the 14-day stochastic is at 73.01% with the period’s ATR at 0.41. The stock’s 9-day MACD Oscillator is pointing at 0.41 and 0.51 on the 14-day charts.
In the most recent analyst report for Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Wells Fargo downgraded it to an Equal weight rating. They previously had an Overweight rating on the stock. Analysts offering their rating for IRWD stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate IRWD as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is IRWD’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $9.00 and a high of $15.00, with their median price target at $13.00. Looking at these predictions, the average price target given by analysts is for Ironwood Pharmaceuticals Inc. (IRWD) stock is $12.60.